Arvinas Holding has the Potential to Gain 50% in 2021

Arvinas is one of the innovators in the biopharmaceutical field. It is working on protein degradation therapeutics. The new class of drugs targets disease-related proteins. They use the body’s own natural protein disposal systems to break down and remove problem proteins.

Arvinas is all about the pipeline, like most research-based biopharma companies. Even though the pipeline here is an early stage, it’s robust, featuring no fewer than 13 programs in the fields of neuroscience, oncology, and immune-oncology. Furthermore, drug candidates under development are in different stages of early research.

Arvinas shares have soared recently, more than doubling their share price. The company released clinical data showing the potential efficacy of two pipeline drugs, causing a boost in share prices. These drugs are ARV-471 and ARV-110. The first one is for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer. The second one is for the treatment of men with metastatic castrate-resistant prostate cancer.

In December 2020, the company also announced the pricing on a new issue of common stock. According to it, Arvinas Holding is putting 5.714 million shares on the market at $70 each to raise $400 million in new capital.

Besides, board member Liam Ratcliffe recently spent $9.99 million on 142,857 shares. His total holding in Arvinas Holding is currently $58.46 million.

Arvina’s average price target

Roth Capital’s analyst Zegbeh Jallah noted that he likes management’s outline of important next steps. They highlight how the company plans to develop ARV-110 and ARV-471 to boost share’s value and build out its early-stage pipeline. The stock’s robust preclinical pipeline is also a nice addition to its strong leading clinical candidates.

Jallah gave the stock a Strong Buy rating. He set his price target at $120, which implies a robust one-year upside of 50%.

Wall Street’s other analysts agree with Jallah, also giving Arvinas a strong-buy rating. The stock’s average price target is currently $102.44, and it suggests a 28% increase over the year.